ChronoScale Holdings Stock Rises 7% On Microsoft AI Deployment Plan

ChronoScale (CHRN), formerly Ekso Bionics, plans to divest its wearable-robotics business. The company, now focused on AI computing, aims to complete the sale by August 31, though uncertainty remains. Ekso Bionics reported $12.8M revenue and $11.7M net loss in 2025. ChronoScale's stock rose 6% on a new Microsoft deal.

Microsoft (MSFT) trades at a premium to the market on earnings, sales, and cash flow, with strong cash conversion. Its Q4 2026 operating cash flow was $55.4B, but free cash flow was $19.6B after $35.8B in capital expenditures, primarily for AI infrastructure. Azure revenue grew 43% YoY, but gross margin fell to 67% due to shifting mix.

Marvell (MRVL) reported Q2 sales of $2.74B, up 37%, and raised its Q3 revenue forecast to $3.15B. Analysts raised price targets to $300 (Rosenblatt) and $265 (Susquehanna). Growth is expected from partnerships with Microsoft, AWS, and Google, including custom AI silicon programs. Risks include execution delays and competitive pressures.

Microsoft appointed Angela Nganga as its East Africa Country Lead. Nganga, based in Nairobi, will oversee AI, digital transformation, and partnerships in Kenya and the broader region. She has held senior roles at Microsoft since 2012 and brings over 20 years of experience. Microsoft aims to expand AI skills and workforce readiness in East Africa.

Chronoscale Corp stock rose 7.0% to $22.64 after announcing a 50-megawatt AI compute partnership with Microsoft, using NVIDIA systems. CEO Chen highlighted the strategic importance. The Nasdaq Composite gained 0.9%, supported by Nvidia's strong earnings. Chronoscale also partnered with Nutanix, boosting its commercial pipeline.

Microsoft advanced its EUR 2 billion data center project in Alsace, France, after receiving a favorable opinion from a public inquiry. The project, announced in mid-2024, now awaits approval from the local prefect despite opposition from environmental groups and some residents.